Aadi Bioscience IncNASDAQ:AADI
- LAST PRICE1.9150
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.9100/ 1
- Ask / Lots1.9500/ 10
- Open / Previous Close0.0000 / 1.9150
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AADI |
|---|---|---|
| 09:32 ET | 989 | 1.855 |
| 09:34 ET | 100 | 1.855 |
| 09:38 ET | 1562 | 1.86 |
| 09:39 ET | 1100 | 1.86 |
| 09:41 ET | 110 | 1.86 |
| 09:59 ET | 100 | 1.86 |
| 10:01 ET | 3590 | 1.9 |
| 10:12 ET | 1800 | 1.8901 |
| 10:14 ET | 700 | 1.9 |
| 10:19 ET | 600 | 1.865 |
| 10:24 ET | 3627 | 1.89 |
| 10:26 ET | 500 | 1.9 |
| 10:28 ET | 300 | 1.91 |
| 10:37 ET | 126 | 1.899 |
| 10:48 ET | 100 | 1.91 |
| 10:51 ET | 440 | 1.8915 |
| 10:53 ET | 2000 | 1.89 |
| 11:04 ET | 2000 | 1.89 |
| 11:11 ET | 100 | 1.89 |
| 11:15 ET | 100 | 1.89 |
| 11:31 ET | 100 | 1.9 |
| 11:44 ET | 100 | 1.9 |
| 11:45 ET | 100 | 1.9 |
| 11:54 ET | 100 | 1.9 |
| 12:00 ET | 100 | 1.9 |
| 12:14 ET | 100 | 1.9 |
| 12:16 ET | 100 | 1.9 |
| 12:30 ET | 100 | 1.9 |
| 12:39 ET | 1850 | 1.9 |
| 12:45 ET | 100 | 1.91 |
| 12:57 ET | 100 | 1.905 |
| 12:59 ET | 1100 | 1.8903 |
| 01:01 ET | 200 | 1.9 |
| 01:06 ET | 245 | 1.8996 |
| 01:17 ET | 1071 | 1.9 |
| 01:26 ET | 143 | 1.8993 |
| 01:28 ET | 535 | 1.9 |
| 01:33 ET | 100 | 1.9 |
| 01:35 ET | 1000 | 1.897 |
| 01:37 ET | 100 | 1.8993 |
| 01:39 ET | 200 | 1.895 |
| 01:50 ET | 2137 | 1.9 |
| 01:51 ET | 100 | 1.91 |
| 01:53 ET | 110 | 1.91 |
| 02:04 ET | 2600 | 1.9199 |
| 02:06 ET | 100 | 1.92 |
| 02:13 ET | 100 | 1.92 |
| 02:18 ET | 1000 | 1.9199 |
| 02:22 ET | 100 | 1.92 |
| 02:24 ET | 2100 | 1.92 |
| 02:31 ET | 2598 | 1.91 |
| 02:44 ET | 1095 | 1.92 |
| 02:58 ET | 100 | 1.92 |
| 03:00 ET | 120 | 1.92 |
| 03:03 ET | 100 | 1.92 |
| 03:07 ET | 103 | 1.9001 |
| 03:16 ET | 200 | 1.92 |
| 03:20 ET | 110 | 1.91 |
| 03:23 ET | 600 | 1.91 |
| 03:25 ET | 100 | 1.915 |
| 03:32 ET | 430 | 1.92 |
| 03:36 ET | 100 | 1.92 |
| 03:43 ET | 4571 | 1.91 |
| 03:50 ET | 100 | 1.915 |
| 03:52 ET | 419 | 1.915 |
| 03:56 ET | 210 | 1.91 |
| 03:57 ET | 600 | 1.91 |
| 03:59 ET | 1485 | 1.915 |
May 8, 2024
Press Release: Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update, from 8:01AM ET on Wednesday May 08, 2024 by Dow Jones
8:01AM ET on Wednesday May 08, 2024 by Dow JonesAadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update, from 8:00AM ET on Wednesday May 08, 2024 by Dow Jones
8:00AM ET on Wednesday May 08, 2024 by Dow Jones
May 1, 2024
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update, from 8:01AM ET on Wednesday May 01, 2024 by Dow Jones
8:01AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aadi Bioscience Inc | 47.0M | -0.7x | --- |
Cara Therapeutics Inc | 44.0M | -0.4x | --- |
Elutia Inc | 78.4M | -1.4x | --- |
Prenetics Global Ltd | 71.5M | -1.3x | --- |
Predictive Technology Group Inc | 209.7K | 0.0x | --- |
Turnstone Biologics Corp | 63.1M | -1.0x | --- |
Company Information
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Contact Information
- Headquarters
- 17383 Sunset Avenue, Suite A250PACIFIC PALISADES, CA, United States 90272
- Phone
- 424-473-8055
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Neil Desai
- Non-Executive Independent Chairman of the Board
- Caley Castelein
- President, Chief Executive Officer, Principal Executive Officer
- David Lennon
- Chief Financial Officer
- Scott Giacobello
- Chief Medical Officer
- Loretta Itri
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.0M |
|---|---|
Revenue (TTM) | $23.8M |
Shares Outstanding | 24.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-2.55 |
Book Value | $4.28 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -313.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
